Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone
No Thumbnail Available
Identifiers
Date
2020-09-01
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
